drugset / Trial / NCT06846255

Comparing DCP and DAP for Pemphigus Vulgaris

NCT06846255

Phase 4 Completed 66 enrolled Jinnah Postgraduate Medical Centre
RandomizedParallel-groupOpen-labelTreatment

Summary

What's the study about? This study focused on comparing two different treatments for pemphigus vulgaris, a skin condition caused when body's immune system works against itself. The treatments were dexamethasone cyclophosphamide pulse (DCP) therapy and dexamethasone azathioprine pulse (DAP) therapy. Why was this study done? The goal of the study was to determine which treatment, DCP or DAP, was more effective in treating pemphigus vulgaris. Both treatments involve high-dose steroids combined with other medications, but they differ in the specific medications used. How did they do the study? Researchers conducted a randomized controlled trial, where patients were randomly assigned to receive either DCP or DAP therapy. They then followed these patients to see how well each treatment worked.

Timeline

Start
2021-06-15
Primary completion
2021-12-15
Completion
2021-12-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azathioprine Small molecule 50 mg Oral
Comparator Cyclophosphamide Other / unclassified 50 mg Intravenous
Comparator Cyclophosphamide Other / unclassified 500 mg Intravenous
Comparator Dexamethasone Small molecule 100 mg Intravenous

Indications